NDAINTRAVENOUSSOLUTION
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
ROCURONIUM BROMIDE (rocuronium bromide) by B. Braun is duration. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rocuronium bromide is a non-depolarizing neuromuscular blocking agent administered intravenously as a solution. It works by competing for cholinergic receptors at the motor end-plate, with effects antagonized by acetylcholinesterase inhibitors like neostigmine and edrophonium. This agent is used during anesthesia to facilitate intubation and provide muscle relaxation during surgical procedures.
Launch13.1 years to LOE
As a newly launched product from B. Braun with 13+ years of patent protection, the brand team is in active growth phase with opportunity to establish market position in the operating room neuromuscular blocking agent category.
Mechanism of Action
duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)
Started Oct 2004
149 enrolled
Anesthesia
Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)
Started Mar 2004
174 enrolled
Anesthesia, General
Career Relevance
Working on rocuronium bromide offers career opportunity in a newly launched specialty pharmaceutical product with strong patent protection and established clinical utility. The operating room and perioperative setting creates direct hospital engagement roles with clear sales metrics and relationship-driven career advancement.
Worked on ROCURONIUM BROMIDE at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.